Amylyx Pharmaceuticals (AMLX) Profit After Tax (2021 - 2026)

Amylyx Pharmaceuticals has reported Profit After Tax for 6 years, with the latest figure at -$43.6 million in Q2 2026.

• On a quarterly basis, Profit After Tax fell 5.31% year-over-year to -$43.6 million in Q2 2026; TTM through Jun 2026 was -$152.3 million, a 18.81% increase from a year earlier, with the FY2025 full-year figure at -$144.7 million, up 52.03% from the prior year.
• Profit After Tax was -$43.6 million for Q2 2026 at Amylyx Pharmaceuticals, down from -$41.3 million in the prior quarter.
• The five-year high for Profit After Tax was $22.1 million in Q2 2023, with the low at -$118.8 million in Q1 2024.
• Average Profit After Tax over 5 years is -$37.8 million, with a median of -$41.4 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2024: Profit After Tax soared 140.83% in 2023, then tumbled 7652.0% in 2024.
• Over 5 years, Profit After Tax stood at -$42.7 million in 2022, then surged by 111.08% to $4.7 million in 2023, then tumbled by 893.62% to -$37.5 million in 2024, then gained by 12.11% to -$33.0 million in 2025, then slumped by 32.26% to -$43.6 million in 2026.
• The last three Profit After Tax figures came in at -$43.6 million (Q2 2026), -$41.3 million (Q1 2026), and -$33.0 million (Q4 2025), per Business Quant data.